Association between *Helicobacter pylori* infection and nonalcoholic fatty liver

A meta-analysis

Rongqiang Liu, MD<sup>a,b</sup>, Qiuli Liu, PhD<sup>c</sup>, Ying He, MD<sup>a</sup>, Wengjing Shi, MD<sup>a</sup>, Qianhui Xu, MD<sup>a</sup>, Qing Yuan, MD<sup>a</sup>, Qi Lin, MD<sup>a</sup>, Biao Li, MD<sup>b</sup>, Lei Ye, MD<sup>a</sup>, Youlan Min, MD<sup>a</sup>, Peiwen Zhu, MD<sup>a</sup>, Yi Shao, PhD<sup>a</sup>

Abstract

Background: Opinion regarding whether *Helicobacter pylori* infection can promote the occurrence and development of nonalcoholic fatty liver (NAFLD) is divided. Therefore, we aimed to assess the exact relationship between *H pylori* infection and NAFLD by integrating all available data.

Methods: The articles about *H pylori* infection and NAFLD were collected by searching the databases of PubMed, Embase, Web of Science, Scopus, China National Knowledge Infrastructure, and WanFang. The random-effects model was used for data analysis, followed by subgroup analysis and meta-regression to explore sources of heterogeneity.

Results: Twenty-one articles were included in the study. Pooled analysis showed that *H pylori* infection indeed promoted NAFLD. Subgroup analysis and regression analysis showed that case-control ratio may be one of the sources of heterogeneity.

Conclusions: *H pylori* infection is indeed one of the factors that promotes the progression of NAFLD for the Asian population. This provides new approaches for clinical prevention and treatment for NAFLD.

Abbreviations: CI = confidence interval, NAFLD = nonalcoholic fatty liver, OR = odds ratio.

Keywords: *Helicobacter pylori*, meta-analysis, nonalcoholic fatty liver

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty lesions in addition to alcohol and other defined liver injury factors. With improving economic stability and lifestyle changes, the incidence of NAFLD is increasing yearly, and its incidence rate is as high as 20% to 30% on a global scale, which seriously affects people’s health. The etiology of NAFLD is complex, primarily characterized by abnormal lipid metabolism, insulin resistance, and genetic factors. In recent years, studies have found that abnormal fat metabolism in the liver can lead to dysbacteriosis of the intestinal flora; dysregulation of the flora leads to disorders of lipid metabolism, which eventually promotes lipid deposition in liver. Moreover, there is increasing evidence that NAFLD is associated with abnormalities of the intestinal flora, especially with *Helicobacter pylori*.

*H pylori* is a gram-negative bacillus colonized in the deep layers of human gastric mucosa. The reported infection rate of *H pylori* is as high as 50% or more worldwide. Studies have shown that *H pylori* is responsible for chronic gastritis, peptic ulcer, gastrointestinal lymphoma, and gastric cancer. In addition, new findings suggest that *H pylori* is closely related to liver tumors, obesity, diabetes, and abnormal lipid metabolism. In recent years, studies have found that *H pylori* infection is one of the factors...
contributing to the progression of NAFLD, and elimination of *H pylori* can delay the progression of NAFLD to some extent.\(^{13–30}\) However, other studies have suggested that *H pylori* infection has no clear relationship with NAFLD, and its eradication does not halt the progression of NAFLD.\(^{31–38}\) Therefore, we further explored the exact relationship between *H pylori* infection and NAFLD by integrating data for meta-analysis.

2. Materials and methods

Two independent researchers searched the PubMed, Embase, Web of Science, Scopus, China National Knowledge Infrastructure, and WanFang Data. The search keywords were: (*Helicobacter pylori* or *H pylori* or *Hp* or *Helicobacter spp* or *H. pylori*) AND (non-alcoholic fatty liver disease or NAFLD or non-alcoholic steatohepatitis or NASH or non-alcoholic fatty liver or NAFL or fatty liver). Articles published from January 2007 to October 2018 were searched. The search method uses keywords, without any restrictions, and manually searched for references in existing literature.

2.1. Inclusion criteria

Papers were included if they:

(1) compared the risk of NAFLD in patients with *H pylori* infection and those without;

(2) provided the number of positive/negative *H pylori* infection persons in the NAFLD and control groups.

2.2. Exclusion criteria

Abstracts, conference papers, and articles detailing animal experiments were excluded, as were articles that did not provide complete data.

In this paper, 2 researchers independently conducted the literature search and extracted the first author of the articles, year of publication, country of publication, method of detection of *H pylori*, method of diagnosis of NAFLD, the number of positive/negative *H pylori* infections in the NAFLD group, and the number of positive/negative *H pylori* infections in the control group. We assessed the quality of each study according to the Newcastle–Ottawa quality assessment scale.\(^{39}\) This study does not require the approval of the ethics committee.

2.3. Data analysis

All data analysis was performed using STATA version 12.0 software (Stata Corporation, College Station, TX), and heterogeneity analysis was performed using a Chi-square test or a Cochrane-\(Q\) test. Heterogeneity was assessed by \(I^2\) statistic, wherein \(I^2 < 50\%\) indicates minor heterogeneity, for which a fixed effect model was used, and \(I^2 > 50\%\) indicates large heterogeneity, for which a random effect model was used. The subgroup analysis and regression analysis were performed to explore sources of heterogeneity. The forest plot assesses the relationship between *H pylori* infection and NAFLD. The funnel plot and Beggs and Egger tests were used to investigate publication bias. \(P < .05\) was considered statistically significant.

3. Results

3.1. Clinical features

By searching the aforementioned databases, we selected 1491 research articles, and further browsed the title, abstract, and full text of the literature. Next, we excluded abstracts, conference articles, animal experiment studies, and those with incomplete data. Eventually, 21 studies were included for the final analysis that researched the relationship between *H pylori* infection and NAFLD. All these articles were published between 2007 January and 2018 October. The related literatures included 2 cohort studies, 2 case-control studies, and 17 cross-sectional studies in the meta-analysis. The flow chart for the studies is shown in Figure 1. A total of 14,623 participants were included, and the sample size for each study ranged from 53 to 43,216. Fourteen articles used the breath test to confirm *H pylori* infection, 7 articles used antibodies to detect *H pylori* infection, 19 articles used ultrasound to confirm NAFLD, and 2 articles used other methods. The basic information about all included literatures is listed in Table 1.

3.2. Meta-analysis and subgroup analysis

A total of 21 articles were included, including 11 reports in English and 10 in Chinese. We conducted a meta-analysis by integrating data to find significant heterogeneity \((I^2 = 95.6\%)\). Therefore, we use the random-effects model to calculate the odds ratio (OR) and 95% confidence intervals (CIs). The results indicated that *H pylori* infection is indeed one of the contributing factors to NAFLD \((P = .000, OR [95\% CI] = 1.529 [1.336, 1.750])\). The forest plot results are described in Figure 2.

There was significant heterogeneity among the studies. To further explore the heterogeneity sources, we performed a subgroup analysis based on the study type, region, *H pylori* detection method, NAFLD detection method, sample size, and case-control ratio. The results of all subgroup analyses are shown in Table 2. Unfortunately, we did not find the cause of heterogeneity in the subgroup analysis.

3.3. Regression analysis

To find the source of heterogeneity, we also performed regression analysis (Table 2). The results showed that the heterogeneity was caused by case-control ratio \((P = .000)\) instead of study type \((P = .658)\), NAFLD test method \((P = .477)\), *H pylori* detection method \((P = .841)\), race \((P = .542)\), publication year \((P = .904)\), or language \((P = .620)\).

3.4. Publication bias

We used a funnel plot to qualitatively detect the publication bias, and Egger and Beggs tests to quantify the publication bias. The funnel plots were almost symmetric (Fig. 3). \(P\)-value of Egger test was .370. \(P\) was greater than .05, and no significant bias was observed.

4. Discussion

NAFLD is characterized by simple fatty liver in the early stage, which can evolve and progress to steatohepatitis, cirrhosis, liver cancer, and liver failure.\(^{40,41}\) It is one of the most common liver diseases that affects people’s life and health.\(^{42}\) Currently, there are some theories to explain how *H pylori* infection causes NAFLD. *H pylori* can upregulate the expression of various inflammatory factors such as tumor necrosis factor, C-reactive protein, and interleukin to promote insulin resistance.\(^{43,44}\) At the same time, *H pylori* can retrograde into the liver through the hepatic bile duct or intestinal ectopic, leading to chronic liver
inflammation, causing liver cell damage and necrosis. The study found that human fetuin A is significantly increased in patients harboring *H. pylori* infection, and human fetuin A is an important participant in insulin signaling, playing a crucial role in promoting insulin resistance and diabetes. In addition, studies have revealed that adiponectin expression is significantly reduced in NAFLD patients infected with *H. pylori*, and adiponectin inhibits fatty acid deposition in the liver and inhibits NF-kB pathway activation as an anti-inflammatory effect. When adiponectin expression is abnormal, fat accumulates more easily in the liver cells, and the liver is more susceptible to inflammatory damage. Studies have also shown that lipids levels can change significantly in patients with *H. pylori* infection; accordingly, dyslipidemia is common in patients with NAFLD.

Our meta-analysis found that *H. pylori* is one of the factors that promote NAFLD progression, which is consistent with the results of a previous meta-analysis. However, the previous meta-analysis only included six articles, 3 of which were conference abstracts, and 2 of these abstracts did not have their full-text released yet. In addition, numerous studies on the association between *H. pylori* infection and NAFLD have emerged since that meta-analysis was published. Therefore, it is necessary to implement a new meta-analysis on this issue. We combined the data and found that the heterogeneity was very obvious, so we adopted a random-effects model. Considering the heterogeneity among the studies, subgroup analyses were performed. Unfortunately, we did not find the reason for this heterogeneity in subgroup analyses. However, the good news was that through regression analysis, we found that the case-control ratio may be a cause of heterogeneity (P = 0.035).

There are several shortcomings in our meta-analysis. First, small sample studies are more prone to generate heterogeneity, and only 8 of the 21 studies in the meta-analysis had over 5000 patients. Second, most of the included researches were cross-sectional studies, and the results of the research are not very strong, which is bound to have a certain impact on our conclusions. Third, the risk factors for NAFLD include dyslipidemia, obesity, age, environment, diet and sex, and additional biochemical features of selected articles cannot be
| Study and year | Country | Age | Study type | Control group | NAFLD group | Case-control ratio | Diagnosis of Helicobacter pylori infection | Diagnosis of NAFLD |
|---------------|---------|-----|------------|---------------|-------------|-------------------|------------------------------------------|------------------|
| Lu 2018[17]   | China   | 54  | Cross-sectional | 199, 397 | 390, 881 | 0.46 | Breath test | Ultrasound |
| Polyzos 2013[18] | Greece | 54.5 | Cross-sectional | 26, 2 | 14, 11 | 1.12 | Antibody | Histology |
| Kim 2017[19]  | Korea   | 49  | Cohort study | 2080, 1301 | 7838, 5809 | 0.25 | Antibody | Ultrasound |
| Abdel-Razik 2018[20] | Egypt | 49.5 | Cohort study | 23, 148 | 0, 198 | 0.87 | Antibody | Ultrasound |
| Kang 2013[21] | Greece | 44  | Case-control | 658, 1065 | 390, 881 | 0.46 | Antibody | Ultrasound |
| Chen 2016[22] | China | NA | Cross-sectional | 313, 290 | 723, 937 | 0.36 | Breath test | Ultrasound |
| Zhang 2016[23] | Korea | 49 | Cohort study | 300, 144 | 456, 1 | Breath test | Ultrasound |
| Zhang 2016[24] | China | 47.5 | Cross-sectional | 809, 1115 | 1649, 3164 | 0.25 | Breath test | Ultrasound |
| Wang 2016[25] | China | 52.5 | Cross-sectional | 224, 132 | 192, 164 | 1 | Breath test | Ultrasound |
| Wang 2016[26] | China | 38  | Cross-sectional | 126, 74 | 37, 163 | 1 | Breath test | Ultrasound |
| Peng 2014[27] | China | 53. | Cross-sectional | 103, 47 | 41, 59 | 1.5 | Breath test | Ultrasound |
| Xu 2011[28]   | China | NA | Cross-sectional | 40, 22 | 14, 36 | 1.24 | Antibody | Ultrasound |
| Hou 2018[29]  | China | NA | Cross-sectional | 3982, 9414 | 5519, 24301 | 0.45 | Breath test | Ultrasound |
| Liu 2014[30]  | China | 50  | Cross-sectional | 1657, 3724 | 2686, 6306 | 0.80 | Breath test | Ultrasound |
| Baeg 2015[31] | Korea | 53  | Cross-sectional | 505, 440 | 1131, 1587 | 0.34 | Breath test | Histology |
| Cai 2018[32]  | China | 38  | Cross-sectional | 145, 288 | 500, 1118 | 0.26 | Breath test | Ultrasound |
| Okushin 2015[33] | Japan | 50 | Cross-sectional | 523, 1279 | 926, 2561 | 0.52 | Antibody | Ultrasound |
| Fan 2018[34]  | China | 48  | Cross-sectional | 3905, 5769 | 6943, 11554 | 0.52 | Breath test | Ultrasound |
| Guo 2013[35]  | China | 49  | Cross-sectional | 809, 115 | 1649, 3164 | 0.39 | Antibody | Ultrasound |
| Wang 2018[36] | China | 45.5 | Cross-sectional | 713, 641 | 902, 1101 | 1 | Breath test | Ultrasound |
| Chen 2016[37] | China | 60  | Cross-sectional | 767, 663 | 1841, 1888 | 0.38 | Breath test | Ultrasound |

NAFLD = nonalcoholic fatty liver.
Table 2
Meta-regression and subgroup analysis of all studies evaluating the association between *Helicobacter pylori* infection and nonalcoholic fatty liver.

| Stratified study                | No. of studies | Fixed-model (95%CI) | Random-model (95%CI) | Heterogeneity | Meta-regression |
|--------------------------------|----------------|---------------------|----------------------|---------------|-----------------|
|                                |                | Pooled OR           |                      | I² (%)        | Tau² P-value    |
|                                |                | Fixed-model (95%CI) |                      | P-value       | Adj R² (%) P-value |
| Year                           |                |                     |                      |               |                 |
| >2016                          | 9              | 1.416 (1.375, 1.458) | 1.564 (1.250, 1.957) | 97.3% .000   | 0.2741 .904     |
| ≤2016                          | 12             | 1.242 (1.192, 1.295) | 1.498 (1.27, 1.768)  | 91.6% .000   |                 |
| Study type                     |                |                     |                      |               |                 |
| Cross-sectional                | 17             | 1.356 (1.321, 1.392) | 1.487 (1.278, 1.732) | 95.9% .000   | 0.2772 .10.25%  |
| Cohort study                   | 2              | 1.205 (1.116, 1.302) | 6.692 (0.137, 327.949) | 87.2% .338   |                 |
| Case-control                   | 2              | 1.667 (1.499, 1.855) | 2.106 (0.961, 4.616) | 97% .063     |                 |
| Diagnosis of *Helicobacter pylori* infection | |                      |                      |               |                 |
| Antibody                       | 7              | 1.225 (1.160, 1.294) | 1.322 (1.091, 1.602) | 83.8% .004   | 0.2795 .11.12%  |
| Breath test                    | 14             | 1.388 (1.351, 1.425) | 1.579 (1.333, 1.870) | 96.7% .000   |                 |
| Diagnosis of NAFLD             |                |                     |                      |               |                 |
| Ultrasound                      | 19             | 1.347 (1.315, 1.381) | 1.507 (1.310, 1.733) | 95.9% .000   | 0.2715 .7.99%   |
| Histology                      | 2              | 1.644 (1.418,1.906) | 3.361 (0.571,19.798) | 79.3% .180   |                 |
| Sample size                    |                |                     |                      |               |                 |
| >5000                          | 8              | 1.3359 (1.301, 1.370) | 1.274 (1.065, 1.523) | 97.7% .008   | 0.2297 .9.06%   |
| ≤5000                          | 13             | 1.475 (1.384, 1.572) | 1.951 (1.501, 2.537) | 92% .000     |                 |
| Race                           |                |                     |                      |               |                 |
| Yellow                         | 18             | 1.348 (1.316, 1.382) | 1.506 (1.307, 1.735) | 96.2% .000   | 0.2592 .9.58%   |
| White                          | 3              | 1.499 (1.332, 1.687) | 6.952 (0.819, 59.028) | 84.4% .231   |                 |
| Language                       |                |                     |                      |               |                 |
| English                        | 11             | 1.225 (1.183, 1.268) | 1.403 (1.215, 1.620) | 90.6% .000   | 0.2622 .4.28%   |
| Chinese                        | 10             | 1.489 (1.440, 1.540) | 1.688 (1.341, 2.125) | 96.8% .000   |                 |
| Case-control ratio             |                |                     |                      |               |                 |
| ≥1                             | 6              | 2.902 (2.474, 3.404) | 3.663 (2.122, 6.322) | 87.9% .000   | 0.6607 .73.73%  |
| <1                             | 15             | 1.330 (1.298, 1.362) | 1.272 (1.116, 1.449) | 95.7% .000   |                 |

CI = confidence interval, NAFLD = nonalcoholic fatty liver, OR = odds ratio.

Figure 3. Begg funnel plot of publication bias.
Liu et al. Medicine (2019) 98:44

extracted, so our data integration for the meta-analysis has not been able to control these factors. Fourth, most of the meta-analysis done is taken from studies done in the Asian region, and the results may be more suitable for the Asian population. In addition, there is no uniform standard for detection of H pylori infection and diagnosis of NAFLD in these studies, and it is likely that there will be some bias in the results owing to different methodologies. Furthermore, different genotypes of H pylori have different effects on NAFLD as mentioned in the study; hence, the effects of different genotypes of H pylori in the articles cannot be excluded. Finally, if it can be proved that eradication of H pylori can effectively prevent NAFLD progression, it can be confirmed from the sidelines that H pylori infection does indeed promote NAFLD.

In conclusion, our meta-analysis by integrating data further confirmed that H pylori infection in the gastrointestinal tract is indeed one of the factors that promotes the progression of NAFLD for the Asian population. However, given that most of the included studies are small-sample, local geographical area and cross-sectional studies, multicenter, wide geographical area and large-sample prospective studies are needed to further explore the relationship between H pylori infection and NAFLD.

Author contributions
Conceptualization: Yi Shao.
Data curation: Yi Shao.
Methodology: Yi Shao.
Writing - original draft: Rongqiang Liu, Qiuli Liu.
Writing - review and editing: Yi Shao.

References
[1] Jain-Gao F. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 2010;18:163–6.
[2] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019;69:2672–82.
[3] Fazel Y, Koeneig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016;65:1017–23.
[4] Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299–314.
[5] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038–48.
[6] Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatology 2016;13:412–25.
[7] Mouzaki M, Bardsma R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease. Curr Drug Targets 2015;16:1324–31.
[8] Cheng DD, He C, Ai HH, et al. The possible role of helicobacter pylori infection in non-alcoholic fatty liver disease. Front Microbiol 2017;8:743.
[9] Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720–41.
[10] Mentis A, Lehours P, Megraud F. Epidemiology and diagnosis of helicobacter pylori infection. Helicobacter 2015;20(Suppl 1):1–7.
[11] Jonaitis L, Pellicano R. Helicobacter pylori and nonmalignant upper gastrointestinal diseases. Helicobacter 2018;23(Suppl 1):e12522.
[12] Liu LP, Sheng XP, Shuai TK, et al. Helicobacter pylori infection and polymorphism of adiponectin gene promoter-11391g/a, superoxide dismutase gene in nonalcoholic fatty liver disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013;62:121–6.
[13] Kim TJ, Sinn DH, Min WY, et al. A cohort study on helicobacter pylori infection and nonalcoholic fatty liver disease. J Gastroenterol 2017;52:1201–10.
[14] Abdel-Razik A, Mousa N, Shabana W, et al. Helicobacter pylori and non-alcoholic fatty liver disease: a new enigma? Helicobacter 2018;23:e12337.
[15] Zhang C, Guo L, Qin Y, et al. Correlation between helicobacter pylori infection and polymorphism of adiponectin gene promoter-11391g/a, superoxide dismutase gene in nonalcoholic fatty liver disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016;41:359–66.
[16] Guo LL, Lu MJ, He X, et al. Correlation between nonalcoholic fatty liver disease and Helicobacter pylori. West China Med J 2016;31:1667–70.
[17] Zhang L, Gao F. The correlation between nonalcoholic fatty liver disease and Helicobacter pylori infection. Chin J Dig 2017;37:43–5.
[18] Peng CY, Sheng XY, Ding HX, et al. Study about the correlation between Helicobacter pylori infection and nonalcoholic fatty liver disease. J Med Res 2018;43:153–6.
[19] Xu H. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease. Chin J Clin Med 2011;20:69–70.
[20] Hou L, Wu Y. The prevalence of non-alcoholic fatty liver disease and its correlation with helicobacter pylori infection in Zhenjiang area. Chin J Gerontol 2018;38:844–5.
[21] Liu AN, Wang LL, Zhang Y, et al. Correlation between nonalcoholic fatty liver disease and Helicobacter pylori infection. Chin J Gastroenterol Hepatol 2014;23:1451–4.
[22] Jamali R, Moifd A, Vahedi H, et al. The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic fatty liver disease: a randomized open-label clinical trial. Hepat Mon 2013;13:e14679.
[23] Baeg MK, Yoon SK, Ko SH, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:2592–600.
[24] Cai O, Huang Z, Li M. Association between helicobacter pylori infection and nonalcoholic fatty liver disease: a single-center clinical study. Gastroenterol Res Pract 2018;2018:8040262.
[25] Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol 2015;15:25.
[26] Fan N, Peng L, Xia Z, et al. Helicobacter pylori infection is not associated with non-alcoholic fatty liver disease: a cross-sectional study in China. Front Microbiol 2018;9:73.
[27] Guo XY, Shi HT, Shi AM, et al. Investigation of helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Chin J Clin Hepatol 2013;600:300–3.
[28] Wang L, Fang N, He YQ, et al. The correlation between Helicobacter pylori infection and nonalcoholic fatty liver disease. Chin J Exp Clin Infect Dis 2016;10:157–61.
Chen CX, Guo CHY, Mao YS, et al. Relationship between nonalcoholic fatty liver disease and Helicobacter pylori infection in middle-aged and elderly people. Chin J Dig 2016;36:839-42.

Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.

Otosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol 2018;31:288-95.

Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010;28:162-8.

Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30:158-62.

Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010;103:190-6.

Nagura H, Ohtani H, Sasano H, et al. The immuno-inflammatory mechanism for tissue injury in inflammatory bowel disease and Helicobacter pylori-infected chronic active gastritis. Roles of the mucosal immune system. Digestion 2001;63(Suppl 1):12-21.

Vcev A, Nakic D, Mrden A, et al. Helicobacter pylori infection and coronary artery disease. Coll Antropol 2007;31:757-60.

Korponay-Szabo IR, Halttunen T, Szalai Z, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004;53:641-8.

Pal D, Dasgupta S, Kundu R, et al. Fetuin-a acts as an endogenous ligand of tlr4 to promote lipid-induced insulin resistance. Nat Med 2012;18:1279-85.

Sujana C, Huth C, Zierer A, et al. Association of fetuin-a with incident type 2 diabetes: results from the Monica/Kora Augsburg Study and a systematic meta-analysis. Eur J Endocrinol 2018;178:389-98.

Manolakis AC, Taaka EK, Kapsoritakis AN, et al. Increased fetuin a levels in helicobacter pylori infection: a missing link between H. pylori and insulin resistance? Diabetologia 2011;54:472-4.

Adolph TE, Grandrcr C, Grabherr F, et al. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci 2017;18:E1649.

Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul) 2018;33:33-43.

Satoh H, Saito Y, Yoshouka E, et al. Helicobacter pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 2010;17:1041–8.

Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Helicobacter pylori and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Clin Gastroenterol 2018;52:386–91.